复发转移性宫颈癌免疫治疗相关进展

doi:10.3760/cma.j.cn371439-20220520-00100

摘要/Abstract

摘要：

免疫治疗主要包括单纯免疫治疗（免疫检查点抑制剂、治疗性人乳头瘤病毒疫苗、过继性T细胞疗法、双免疫治疗等）和免疫联合其他治疗（如化疗、抗血管生成治疗、放疗等）。免疫治疗的不断发展以及治疗方案的完善,可改善患者的生存和预后,为复发转移性宫颈癌的诊治提供新的思路。

关键词: 宫颈肿瘤, 复发, 肿瘤转移, 免疫疗法, 治疗学

Abstract:

Immunotherapy mainly includes simple immunotherapy （immune checkpoint inhibitor, therapeutic human papillomavirus vaccine, adoptive T cell therapy, double immunotherapy, etc.）, immuno-therapy combined with other treatments （such as chemotherapy, antiangiogenic therapy, radiotherapy, etc.）. The continuous development of immunotherapy and the improvement of treatment scheme have improved the survival and prognosis of patients, and provided new ideas for the diagnosis and treatment of recurrent and metastatic cervical cancer.

Key words: Uterine cervical neoplasms, Recurrence, Neoplasm metastasis, Immunotherapy, Therapeutics

张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.

Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.

参考文献 34

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines[J]. Obstet Gynecol, 2019, 134(1): 49-57. DOI: 10.1097/AOG.0000000000003311. doi: 10.1097/AOG.0000000000003311 pmid: 31188324
[3]	Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance[J]. Nat Immunol, 2022, 23(5): 660-670. DOI: 10.1038/s41590-022-01141-1. doi: 10.1038/s41590-022-01141-1 pmid: 35241833
[4]	Berger KN, Pu JJ. PD-1 pathway and its clinical application: a 20 year journey after discovery of the complete human PD-1 gene[J]. Gene, 2018, 638: 20-25. DOI: 10.1016/j.gene.2017.09.050. doi: 10.1016/j.gene.2017.09.050
[5]	Im K, Combes AJ, Spitzer MH, et al. Archetypes of checkpoint-responsive immunity[J]. Trends Immunol, 2021, 42(11): 960-974. DOI: 10.1016/j.it.2021.09.007. doi: 10.1016/j.it.2021.09.007 pmid: 34642094
[6]	Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi: 10.1200/JCO.2017.74.5471
[7]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[8]	Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy[J]. Blood, 2018, 131(1): 58-67. DOI: 10. 1182/blood-2017-06-741033. doi: 10.1182/blood-2017-06-741033 pmid: 29118008
[9]	Lheureux S, Butler MO, Clarke B, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi: 10.1001/jamaoncol.2017.3776
[10]	Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4[J]. Mol Cancer, 2019, 18(1): 155. DOI: 10.1186/s12943-019-1091-2. doi: 10.1186/s12943-019-1091-2 pmid: 31690319
[11]	Akhatova A, Chan CK, Azizan A, et al. The efficacy of therapeutic DNA vaccines expressing the human papillomavirus E6 and E7 oncoproteins for treatment of cervical cancer: systematic review[J]. Vaccines (Basel), 2021, 10(1): 53. DOI: 10.3390/vaccines10010053. doi: 10.3390/vaccines10010053
[12]	Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients[J]. Nat Commun, 2014, 5: 5317. DOI: 10.1038/ncomms6317. doi: 10.1038/ncomms6317 pmid: 25354725
[13]	Hasan Y, Furtado L, Tergas A, et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 107(3): 487-498. DOI: 10.1016/j.ijrobp.2020.02.031. doi: 10.1016/j.ijrobp.2020.02.031
[14]	Alvarez RD, Huh WK, Bae S, et al. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16⁺ cervical intraepithelial neoplasia 2/3 (CIN2/3)[J]. Gynecol Oncol, 2016, 140(2): 245-252. DOI: 10.1016/j.ygyno.2015.11.026. doi: 10.1016/j.ygyno.2015.11.026 pmid: 26616223
[15]	Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells[J]. J Clin Oncol, 2015, 33(14): 1543-1550. DOI: 10.1200/JCO.2014.58.9093. doi: 10.1200/JCO.2014.58.9093 pmid: 25823737
[16]	Stevanović S, Helman SR, Wunderlich JR, et al. A phase Ⅱ study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493. DOI: 10.1158/1078-0432.CCR-18-2722. doi: 10.1158/1078-0432.CCR-18-2722 pmid: 30518633
[17]	Jin BY, Campbell TE, Draper LM, et al. Engineered T cells targe-ting E7 mediate regression of human papillomavirus cancers in a murine model[J]. JCI Insight, 2018, 3(8): e99488. DOI: 10.1172/jci.insight.99488. doi: 10.1172/jci.insight.99488
[18]	Naumann RW, Oaknin A, Meyer T, et al. LBA62-Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358[J]. Ann Oncol, 2019, 30(Supplement 5): v898-v899. DOI: 10.1093/annonc/mdz394.059. doi: 10.1093/annonc/mdz394.059
[19]	O'Malley D, Neffa M, Monk BJ, et al. 724MO balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): final results from a phase Ⅱ study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)[J]. Ann Oncol, 2021, 32: S727. DOI: 10.1016/j.annonc.2021.08.1167. doi: 10.1016/j.annonc.2021.08.1167
[20]	Bose CK. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer[J]. Med Oncol, 2022, 39(4): 47. DOI: 10.1007/s12032-022-01646-7. doi: 10.1007/s12032-022-01646-7 pmid: 35092506
[21]	Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641. DOI: 10.1200/JCO.2017.75.3384. doi: 10.1200/JCO.2017.75.3384 pmid: 29337640
[22]	Toor SM, Elkord E. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer[J]. Immunol Cell Biol, 2018, 96(9): 888-897. DOI: 10.1111/imcb.12054. doi: 10.1111/imcb.12054 pmid: 29635843
[23]	周晖, 刘昀昀, 罗铭, 等. 《2022NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(12): 1220-1226. DOI: 10.19538/j.fk2021120112. doi: 10.19538/j.fk2021120112
[24]	Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435. doi: 10.1056/NEJMoa2112435
[25]	Kagabu M, Nagasawa T, Sato C, et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions[J]. Int J Mol Sci, 2020, 21(7): 2335. DOI: 10.3390/ijms21072335. doi: 10.3390/ijms21072335
[26]	Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa[J]. Nat Rev Clin Oncol, 2018, 15(5): 310-324. DOI: 10.1038/nrclinonc.2018.9. doi: 10.1038/nrclinonc.2018.9 pmid: 29434333
[27]	Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106. DOI: 10.1200/JCO.20.01920. doi: 10.1200/JCO.20.01920
[28]	Friedman CF, Snyder Charen A, Zhou Q, et al. Phase Ⅱ study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer[J]. J Immunother Cancer, 2020, 8(2): e001126. DOI: 10.1136/jitc-2020-001126. doi: 10.1136/jitc-2020-001126
[29]	Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase Ⅲ trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage ⅣB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)[J]. Int J Gynecol Cancer, 2020, 30(1): 139-143. DOI: 10.1136/ijgc-2019-000880. doi: 10.1136/ijgc-2019-000880
[30]	Dyer BA, Feng CH, Eskander R, et al. Current status of clinical trials for cervical and uterine cancer using immunotherapy combined with radiation[J]. Int J Radiat Oncol Biol Phys, 2021, 109(2): 396-412. DOI: 10.1016/j.ijrobp.2020.09.016. doi: 10.1016/j.ijrobp.2020.09.016
[31]	Liu Y, Dong Y, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors[J]. J Hematol Oncol, 2018, 11(1): 104. DOI: 10.1186/s13045-018-0647-8. doi: 10.1186/s13045-018-0647-8
[32]	Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer[J]. Semin Radiat Oncol, 2020, 30(4): 273-280. DOI: 10.1016/j.semradonc.2020.05.003. doi: S1053-4296(20)30036-9 pmid: 32828383
[33]	中华医学会妇科肿瘤学分会. 妇科肿瘤免疫检查点抑制剂临床应用指南[J]. 协和医学杂志, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683. doi: 10.12290/xhyxzz.2021-0683
[34]	Verma V, Cushman TR, Tang C, et al. Toxicity of radiation and immunotherapy combinations[J]. Adv Radiat Oncol, 2018, 3(4): 506-511. DOI: 10.1016/j.adro.2018.08.003. doi: 10.1016/j.adro.2018.08.003 pmid: 30370349